The Endothelin System: A Critical Player in the Pathophysiology of Preeclampsia

Current Hypertension Reports

Volumn 20, Issue 4, 2018, Pages

  Granger, Joey P ^a,b   Spradley, Frank T ^a,b   Bakrania, Bhavisha A ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Cardiovascular; Endothelin; Endothelium; Hypertension; Placenta; Preeclampsia; Pregnancy; Vascular smooth muscle

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR; VASCULOTROPIN RECEPTOR 1; ENDOTHELIN;

DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE; VASCULAR ENDOTHELIUM; FEMALE; ISCHEMIA; METABOLISM; PHYSIOLOGY; PLACENTA; VASCULARIZATION;

ENDOTHELINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; ISCHEMIA; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

EID: 85045259728     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-018-0828-4     Document Type: Review

References (70)

1. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–31. https://doi.org/10.1097/01.AOG.0000437382.03963.88.
2. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens. 1991;4(8):700–8.
3. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf). 2013;208(3):224–33. https://doi.org/10.1111/apha.12106.
4. Salam RA, Das JK, Ali A, Bhaumik S, Lassi ZS. Diagnosis and management of preeclampsia in community settings in low and middle-income countries. J Fam Med Prim Care. 2015;4(4):501–6. https://doi.org/10.4103/2249-4863.174265.
5. Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32(3):454–63. https://doi.org/10.1097/HJH.0000000000000069.
6. Institute of Medicine. Improving birth outcomes: meeting the challenge in the developing world. Washington, DC: The National Academies Press; 2003. https://doi.org/10.17226/10841.
7. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1:177–91.
8. Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension. 2013;62(4):666–73. https://doi.org/10.1161/HYPERTENSIONAHA.113.00588.
9. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68(2):357–418. https://doi.org/10.1124/pr.115.011833.
10. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267(23):16066–8.
11. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227–37.
12. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther. 2005;315(3):1058–64. https://doi.org/10.1124/jpet.105.091728.
13. Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW. Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension. 2000;35(1 Pt 2):280–6.
14. Taylor TA, Gariepy CE, Pollock DM, Pollock JS. Gender differences in ET and NOS systems in ETB receptor-deficient rats: effect of a high salt diet. Hypertension. 2003;41(3 Pt 2):657–62. https://doi.org/10.1161/01.HYP.0000048193.85814.78.
15. Wolff K, Faxen M, Lunell NO, Nisell H, Lindblom B. Endothelin receptor type A and B gene expression in human nonpregnant, term pregnant, and preeclamptic uterus. Am J Obstet Gynecol. 1996;175(5):1295–300.
16. Wolff K, Nisell H, Modin A, Lundberg JM, Lunell NO, Lindblom B. Contractile effects of endothelin 1 and endothelin 3 on myometrium and small intramyometrial arteries of pregnant women at term. Gynecol Obstet Investig. 1993;36(3):166–71.
17. Osada K, Tsunoda H, Miyauchi T, Sugishita Y, Kubo T, Goto K. Pregnancy increases ET-1-induced contraction and changes receptor subtypes in uterine smooth muscle in humans. Am J Phys. 1997;272(2 Pt 2):R541–8. https://doi.org/10.1152/ajpregu.1997.272.2.R541.
18. Bourgeois C, Robert B, Rebourcet R, Mondon F, Mignot TM, Duc-Goiran P, et al. Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3. J Clin Endocrinol Metab. 1997;82(9):3116–23. https://doi.org/10.1210/jcem.82.9.4209.
19. Thaete LG, Neerhof MG. Endothelin and blood pressure regulation in the female rat: studies in normal pregnancy and with nitric oxide synthase inhibition-induced hypertension. Hypertens Pregnancy. 2000;19(2):233–47.
20. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension. 2001;37(2 Pt 2):485–9.
21. Kohnen G, Campbell S, Irvine GA, Church HJ, MacLachlan F, Titterington M, et al. Endothelin receptor expression in human decidua. Mol Hum Reprod. 1998;4(2):185–93.
22. Kerchner LJ, Novak J, Hanley-Yanez K, Doty KD, Danielson LA, Conrad KP. Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. Endocrinology. 2005;146(6):2791–7. https://doi.org/10.1210/en.2004-1602.
23. Mazzuca MQ, Dang Y, Khalil RA. Enhanced endothelin receptor type B-mediated vasodilation and underlying [Ca(2)(+)]i in mesenteric microvessels of pregnant rats. Br J Pharmacol. 2013;169(6):1335–51. https://doi.org/10.1111/bph.12225.
24. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension. 2011;57(6):1151–60. https://doi.org/10.1161/HYPERTENSIONAHA.110.165027.
25. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol. 2011;301(2):R267–75. https://doi.org/10.1152/ajpregu.00156.2011.
26. Dent EA, Spradley FT, Granger JP. Endothelin receptor type B (ETB)-deficient pregnant rats have exaggerated placental ischemia-induced hypertension. FASEB J. 2017;31(1 Supplement):851.8.
27. Jeyabalan A, Novak J, Doty KD, Matthews J, Fisher MC, Kerchner LJ, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology. 2007;148(1):189–97. https://doi.org/10.1210/en.2006-0989.
28. Conrad KP, Davison JM. The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? Am J Physiol Renal Physiol. 2014;306(10):F1121–35. https://doi.org/10.1152/ajprenal.00042.2014.
29. Deng A, Conrad KP, Baylis C. Relaxin mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure. Am J Physiol Regul Integr Comp Physiol. 2017;314:R147–52. https://doi.org/10.1152/ajpregu.00148.2017.
30. Inscho EW, Imig JD, Cook AK, Pollock DM. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol. 2005;146(7):1019–26. https://doi.org/10.1038/sj.bjp.0706412.
31. Schildroth J, Rettig-Zimmermann J, Kalk P, Steege A, Fahling M, Sendeski M, et al. Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. Nephrol Dial Transplant. 2011;26(3):779–89. https://doi.org/10.1093/ndt/gfq534.
32. West CA, Sasser JM, Baylis C. The enigma of continual plasma volume expansion in pregnancy: critical role of the renin-angiotensin-aldosterone system. Am J Physiol Renal Physiol. 2016;311(6):F1125–F34. https://doi.org/10.1152/ajprenal.00129.2016.
33. Tamas P, Worgall S, Sulyok E, Rascher W. Renal electrolyte and water handling in normal pregnancy: possible role of endothelin-1. Eur J Obstet Gynecol Reprod Biol. 1994;55(2):89–95.
34. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens. 2011;24(9):964–9. https://doi.org/10.1038/ajh.2011.99.
35. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension. 2012;60(2):507–11. https://doi.org/10.1161/HYPERTENSIONAHA.112.194845.
36. George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens. 2012;21(2):157–62. https://doi.org/10.1097/MNH.0b013e328350094b.
37. Benigni A, Orisio S, Gaspari F, Frusca T, Amuso G, Remuzzi G. Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br J Obstet Gynaecol. 1992;99(10):798–802.
38. Mastrogiannis DS, O'Brien WF, Krammer J, Benoit R. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gynecol. 1991;165(6 Pt 1):1711–6.
39. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 1990;71(6):1675–7. https://doi.org/10.1210/jcem-71-6-1675.
40. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–23. https://doi.org/10.1161/HYPERTENSIONAHA.115.05267.
41. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens. 2012;26(4):236–41. https://doi.org/10.1038/jhh.2011.29.
42. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55(2):394–8. https://doi.org/10.1161/HYPERTENSIONAHA.109.141473.
43. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9(6):480–5.
44. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009;54(4):905–9. https://doi.org/10.1161/HYPERTENSIONAHA.109.137935.
45. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013;61(2):488–93. https://doi.org/10.1161/HYPERTENSIONAHA.111.00055.
46. Nugent WH, Mishra N, Strauss JF 3rd, Walsh SW. Matrix metalloproteinase 1 causes vasoconstriction and enhances vessel reactivity to angiotensin II via protease-activated receptor 1. Reprod Sci. 2016;23(4):542–8. https://doi.org/10.1177/1933719115607998.
47. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP. L-Arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension. 2004;43(4):832–6. https://doi.org/10.1161/01.HYP.0000119192.32360.a9.
48. Taylor RN, Roberts JM, Cunningham FG, Lindheimer MD, Chesley LC. Chesley’s hypertensive disorders in pregnancy. 4th ed. Amsterdam: Elsevier/AP, Academic Press is an imprint of Elsevier; 2015.
49. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med. 2006;122:383–92.
50. •• Spradley FT, Tan AY, Joo WS, Daniels G, Kussie P, Karumanchi SA, et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension. 2016;67(4):740–7. https://doi.org/10.1161/HYPERTENSIONAHA.115.06783. This was the first study to implicate recombinant human placental growth factor as a potential treatment for preeclampsia in a model of placental ischemia-induced hypertension.
51. Makris A, Yeung KR, Lim SM, Sunderland N, Heffernan S, Thompson JF, et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension. 2016;67(6):1263–72. https://doi.org/10.1161/HYPERTENSIONAHA.116.07286.
52. Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension. 2006;47(3):615–8. https://doi.org/10.1161/01.HYP.0000197950.42301.dd.
53. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN Jr, et al. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011;204(4):330 e1–4. https://doi.org/10.1016/j.ajog.2011.01.049.
54. Zhou J, Xiao D, Hu Y, Wang Z, Paradis A, Mata-Greenwood E, et al. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension. 2013;62(3):599–607. https://doi.org/10.1161/HYPERTENSIONAHA.113.01449.
55. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58(2):295–302. https://doi.org/10.1161/HYPERTENSIONAHA.111.173559.
56. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59(1):151–7. https://doi.org/10.1161/HYPERTENSIONAHA.111.182220.
57. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534–43. https://doi.org/10.1111/j.1600-0897.2010.00831.x.
58. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta. 2012;33(Suppl):S48–54. https://doi.org/10.1016/j.placenta.2011.12.006.
59. Bakrania BA, Spradley FT, Satchell SC, Stec DE, Rimoldi JM, Gadepalli RSV, et al. Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells. Am J Physiol Regul Integr Comp Physiol. 2017; https://doi.org/10.1152/ajpregu.00370.2017.
60. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension. 2005;46(1):82–6. https://doi.org/10.1161/01.HYP.0000169152.59854.36.
61. Wang W, Parchim NF, Iriyama T, Luo R, Zhao C, Liu C, et al. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension. 2014;63(3):595–606. https://doi.org/10.1161/HYPERTENSIONAHA.113.02458.
62. Zhou CC, Irani RA, Dai Y, Blackwell SC, Hicks MJ, Ramin SM, et al. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol. 2011;186(10):6024–34. https://doi.org/10.4049/jimmunol.1004026.
63. • Mirabito Colafella KM. Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk? Clin Sci (Lond). 2018;132(1):33–6. https://doi.org/10.1042/CS20171366. This review highlights the importance of studying Endothelin type B receptors in the pathogenesis of preeclampsia, and the therapeutic potential of these receptors.
64. Mazzuca MQ, Li W, Reslan OM, Yu P, Mata KM, Khalil RA. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension. 2014;64(3):632–43. https://doi.org/10.1161/HYPERTENSIONAHA.114.03315.
65. • Gillis EE, Mooney JN, Garrett MR, Granger JP, Sasser JM. Sildenafil treatment ameliorates the maternal syndrome of preeclampsia and rescues fetal growth in the dahl salt-sensitive rat. Hypertension. 2016;67(3):647–53. https://doi.org/10.1161/HYPERTENSIONAHA.115.06071. This study characterizes a novel pre-clinical model of super-imposed preeclampsia in the Dahl Salt-Sensitive Rat.
66. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, et al. Cranial and cardiac neural crest defects in endothelin—a receptor-deficient mice. Development. 1998;125(5):813–24.
67. Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2009;10(11):1847–58. https://doi.org/10.1517/14656560903061275.
68. Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci. 2003;74(2–3):405–9.
69. Thaete LG, Khan S, Synowiec S, Dayton BD, Bauch J, Neerhof MG. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci. 2012;91(13–14):583–6. https://doi.org/10.1016/j.lfs.2012.02.018.
70. Bidwell GL 3rd, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014;5:201. https://doi.org/10.3389/fphar.2014.00201.